SAREPTA THERAPEUTICS INC (SRPT) Stock Fundamental Analysis

NASDAQ:SRPT • US8036071004

16.76 USD
-0.69 (-3.95%)
At close: Feb 27, 2026
16.71 USD
-0.05 (-0.3%)
After Hours: 2/27/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

SRPT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. SRPT has a bad profitability rating. Also its financial health evaluation is rather negative. SRPT has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year SRPT has reported negative net income.
  • SRPT had a negative operating cash flow in the past year.
  • In the past 5 years SRPT reported 4 times negative net income.
  • In the past 5 years SRPT always reported negative operating cash flow.
SRPT Yearly Net Income VS EBIT VS OCF VS FCFSRPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

  • SRPT has a Return On Assets of -7.77%. This is amongst the best in the industry. SRPT outperforms 85.41% of its industry peers.
  • SRPT has a Return On Equity of -20.57%. This is amongst the best in the industry. SRPT outperforms 83.30% of its industry peers.
Industry RankSector Rank
ROA -7.77%
ROE -20.57%
ROIC N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
SRPT Yearly ROA, ROE, ROICSRPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

  • The Gross Margin of SRPT (76.25%) is better than 84.45% of its industry peers.
  • In the last couple of years the Gross Margin of SRPT has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for SRPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
SRPT Yearly Profit, Operating, Gross MarginsSRPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for SRPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SRPT Yearly Shares OutstandingSRPT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SRPT Yearly Total Debt VS Total AssetsSRPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

  • Based on the Altman-Z score of -0.13, we must say that SRPT is in the distress zone and has some risk of bankruptcy.
  • SRPT has a Altman-Z score (-0.13) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.78 indicates that SRPT is somewhat dependend on debt financing.
  • SRPT has a worse Debt to Equity ratio (0.78) than 71.98% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Altman-Z -0.13
ROIC/WACCN/A
WACC7.02%
SRPT Yearly LT Debt VS Equity VS FCFSRPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 2.95 indicates that SRPT has no problem at all paying its short term obligations.
  • SRPT has a Current ratio of 2.95. This is in the lower half of the industry: SRPT underperforms 65.07% of its industry peers.
  • SRPT has a Quick Ratio of 1.79. This is a normal value and indicates that SRPT is financially healthy and should not expect problems in meeting its short term obligations.
  • SRPT has a worse Quick ratio (1.79) than 76.97% of its industry peers.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 1.79
SRPT Yearly Current Assets VS Current LiabilitesSRPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • SRPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -376.32%.
EPS 1Y (TTM)-376.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-338.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-32.73%

3.2 Future

  • Based on estimates for the next years, SRPT will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.03% on average per year.
  • The Revenue is expected to decrease by -7.68% on average over the next years.
EPS Next Y144.16%
EPS Next 2Y55.24%
EPS Next 3Y35.07%
EPS Next 5Y19.03%
Revenue Next Year-25.36%
Revenue Next 2Y-15.7%
Revenue Next 3Y-13.72%
Revenue Next 5Y-7.68%

3.3 Evolution

SRPT Yearly Revenue VS EstimatesSRPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
SRPT Yearly EPS VS EstimatesSRPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SRPT. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 6.02, the valuation of SRPT can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, SRPT is valued cheaply inside the industry as 98.46% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 28.06. SRPT is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 6.02
SRPT Price Earnings VS Forward Price EarningsSRPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRPT Per share dataSRPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

  • SRPT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • SRPT's earnings are expected to grow with 35.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y55.24%
EPS Next 3Y35.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for SRPT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SAREPTA THERAPEUTICS INC

NASDAQ:SRPT (2/27/2026, 8:00:00 PM)

After market: 16.71 -0.05 (-0.3%)

16.76

-0.69 (-3.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-04
Inst Owners84.9%
Inst Owner Change2.78%
Ins Owners5.13%
Ins Owner Change19.53%
Market Cap1.76B
Revenue(TTM)N/A
Net Income(TTM)-271.51M
Analysts67.27
Price Target30.93 (84.55%)
Short Float %22.36%
Short Ratio7.63
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)122.82%
Min EPS beat(2)98.8%
Max EPS beat(2)146.84%
EPS beat(4)2
Avg EPS beat(4)-38.28%
Min EPS beat(4)-376.26%
Max EPS beat(4)146.84%
EPS beat(8)6
Avg EPS beat(8)621.83%
EPS beat(12)9
Avg EPS beat(12)401.46%
EPS beat(16)10
Avg EPS beat(16)286.26%
Revenue beat(2)2
Avg Revenue beat(2)14.32%
Min Revenue beat(2)13.04%
Max Revenue beat(2)15.59%
Revenue beat(4)4
Avg Revenue beat(4)9.59%
Min Revenue beat(4)2.86%
Max Revenue beat(4)15.59%
Revenue beat(8)7
Avg Revenue beat(8)6.15%
Revenue beat(12)10
Avg Revenue beat(12)5.55%
Revenue beat(16)12
Avg Revenue beat(16)4.13%
PT rev (1m)2.16%
PT rev (3m)-3.44%
EPS NQ rev (1m)0.86%
EPS NQ rev (3m)4.49%
EPS NY rev (1m)-1.83%
EPS NY rev (3m)-25.86%
Revenue NQ rev (1m)0.88%
Revenue NQ rev (3m)3.76%
Revenue NY rev (1m)0.18%
Revenue NY rev (3m)4.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 6.02
P/S 0.73
P/FCF N/A
P/OCF N/A
P/B 1.33
P/tB 1.36
EV/EBITDA N/A
EPS(TTM)-6.3
EYN/A
EPS(NY)2.78
Fwd EY16.6%
FCF(TTM)-3.71
FCFYN/A
OCF(TTM)-2.33
OCFYN/A
SpS23.03
BVpS12.6
TBVpS12.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.77%
ROE -20.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.25%
FCFM N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score3
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 290.01%
Cap/Sales 5.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.95
Quick Ratio 1.79
Altman-Z -0.13
F-Score3
WACC7.02%
ROIC/WACCN/A
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-376.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-338.67%
EPS Next Y144.16%
EPS Next 2Y55.24%
EPS Next 3Y35.07%
EPS Next 5Y19.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-32.73%
Revenue Next Year-25.36%
Revenue Next 2Y-15.7%
Revenue Next 3Y-13.72%
Revenue Next 5Y-7.68%
EBIT growth 1Y-206.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-268.11%
EBIT Next 3Y7.84%
EBIT Next 5Y4.7%
FCF growth 1Y36.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.58%
OCF growth 3YN/A
OCF growth 5YN/A

SAREPTA THERAPEUTICS INC / SRPT FAQ

What is the ChartMill fundamental rating of SAREPTA THERAPEUTICS INC (SRPT) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SRPT.


Can you provide the valuation status for SAREPTA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 4 / 10 to SAREPTA THERAPEUTICS INC (SRPT). This can be considered as Fairly Valued.


What is the profitability of SRPT stock?

SAREPTA THERAPEUTICS INC (SRPT) has a profitability rating of 3 / 10.


How financially healthy is SAREPTA THERAPEUTICS INC?

The financial health rating of SAREPTA THERAPEUTICS INC (SRPT) is 2 / 10.